SQSTM1 and ovarian cancer: Although bortezomib treatment increased p62 levels in all of eight studied ovarian cancer cell lines, the changes in phospho-ERK and cathepsin B were not consistent in few ovarian cancer cell lines (Supplementary Figure 3), suggesting that additional regulatory mechanisms for cathepsin B exist.